During the past 12 months, Astellas Pharma's average Dividends Per Share Growth Rate was 5.40% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 9.10% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 13.50% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 10.20% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Astellas Pharma was 52.50% per year. The lowest was 1.30% per year. And the median was 7.60% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Astellas Pharma Forward Dividend Yield % Related Terms
ALPMF vs LLY, JNJ, ABBV: Forward Dividend Yield % Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Astellas Pharma Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
JPY 39.000000
2026-03-30
2026-03-31
2026-06-03
Cash Dividend
semi-annually
JPY:USD 0.006286
JPY 39.000000
2025-09-29
2025-09-30
2025-12-01
Cash Dividend
semi-annually
JPY:USD 0.006758
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Astellas Pharma's Forward Annual Dividend Yield (%) for Today is calculated as
Forward Annual Dividend Yield
=
Forward Full Year Dividend
/
Current Share Price
=
0.490308
/
14.20
=
3.45 %
Current Share Price is $14.20. Astellas Pharma's Dividends per Share for the forward twelve months is calculated as $0.245154 * 2 = $0.490308.
Astellas Pharma's Trailing Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Dividend Yield % of 3.55% mean?
Astellas Pharma (ALPMF) has a Forward Dividend Yield % of 3.55% as of Jun. 25, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Astellas Pharma and its competitors. According to the industry distribution chart, Astellas Pharma ranks #125 out of 504 companies in the Drug Manufacturers industry, placing it in the top 24.8%.
Is Astellas Pharma's Forward Dividend Yield % too high?
Astellas Pharma's current Forward Dividend Yield % is 3.55%. The Drug Manufacturers industry median Forward Dividend Yield % is 2.10. Astellas Pharma's value of 3.55% is 69.5% above this industry median. Based on the distribution chart, Astellas Pharma ranks #125 out of 504 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Astellas Pharma has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Forward Dividend Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #125 out of 504 companies for Forward Dividend Yield %. This places Astellas Pharma in the top 25% of its industry — outperforming the majority of peers. The industry median Forward Dividend Yield % is 2.10. Astellas Pharma's value of 3.55% is 69.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.10, based on 504 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current Forward Dividend Yield % of 3.55% is 69.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current Forward Dividend Yield % is 3.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.18, compared to a current price of $14.20 — trading 0.1% above its estimated fair value. The current Forward Dividend Yield % is 3.55% and 69.5% above the Drug Manufacturers industry median of 2.10. Astellas Pharma's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Forward Dividend Yield % is 3.55% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued.
The current stock price of $14.20 is trading 0.1% above its estimated GF Value™ of $14.18.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
Forward Dividend Yield %: 3.55%
GF Value™: $14.18 vs. price of $14.20 (0.1% above fair value)
Industry Position: 69.5% above the Drug Manufacturers median (#125 of 504)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
73GF Score
Get the complete analysis for ALPMF
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 